Cancer Diagnostics Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Companies Analysis
Buy NowCancer Diagnostics Market Size
Cancer Diagnostic Market is expected to increase in global worth from USD $171.99 billion in 2023 to USD $280.37 billion in 2030, with a Compound Annual Growth Rate of 7.23 % between 2024-2030. This growth is contributed by raising tendencies of cancer, improvements in the diagnostic tools, and consciousness of the early identification strategies. Engaging the constant increase in demand for personalized medicine and advancement in imaging services do help in expanding the market opportunity while categorizing cancer diagnostics as an inevitable segment in healthcare for early detection and better patient outcomes.
Cancer is one of the pinnacle causes of mortality worldwide, and its incidence is increasing alarmingly, expanding the growth of the market. As per the International Agency for Research on Cancer (IARC), there have been an envisioned 20 million new cancer instances and 9.7 million deaths. The predicted quantity of those alive within five years following a cancer analysis became 53.5 million. About 1 in 5 individuals increase cancer in their lifetime. As a result, healthcare specialists are focusing on growing efficient remedies and analysis responses to reduce the prevalence extent. Early detection improves remedy regimen success rates. Consequently, healthcare institutions and business companies are pushing routine tests through specific attention efforts.
Growth Driver in the Cancer Diagnostics Market
Rising Cancer Prevalence
Population concern is the rising number of cancer patients across the global market is the key driver of the growth of the cancer diagnostics market. Cancer incidence also increases with age, and due to factors, such as smoking, poor diet, and lack of physical activity the threat of cancer continues to increase making it increasingly important to have efficient diagnostic methods and solutions. This means early intervention is critical in improving the state of treatment and survival, leading to governments and other players in the delivery of health care investing in diagnostics. People living with cancer are always encouraged to undertake screening programs, imaging tests, and biomarker diagnostics, which expounds this demand. It is estimated that in 2022, close to 20 million new cancer diagnosis were recorded and this is estimated to reach 29.9 million by the year 2040. Demographer Nigel GCELL reports that by the year 2050 the number of affected cases is expected to hit 35 million.
Technological Advancements in Diagnostics
Liquid biopsies, NGS and other imaging technologies are the new trends that are shaping the cancer diagnostics market. These modern technologies suggest more accurate, invasive and faster approaches to the diagnosis of the cancer and its types and stages. Besides, using a huge amount of medical imaging and genetic information, AI and machine learning algorithms improve the accuracy of the diagnosis as well. With advancements in technologies, especially the affordability and availability of these machines, these markets tend to grow greatly since patients are treated according to their individual needs and in turn, patients have better results. In Sept 2024, through the further development of its digital pathology open environment more than 20 advanced AI algorithms from eight new collaborators were added. Such collaborations include strategic partnerships where the main intent focuses in assisting pathologists and scientists who work within the context of cancers through use of AI technologies.
Government Initiatives and Funding
Support from the Government and adequate funding facility for the cancer diagnostics are the key factors fueling the growth of the market. Most nations are designing national screening programs and policies in the attempt to decrease the mortality rates of cancer. Government and other health care facilities involved in the care of the population are expanding their funding for research to improve diagnostic techniques and to increase the availability of the diagnostic stage. Cancer diagnostic technologies contain grants, subsidies, and private corporate and public health collaborations that are driving innovation. These actions raise the availability of diagnostics and the understanding of the need for early diagnosis, which in turn contributes to growth of the market. February 2024, the government revealed new Children and Young People Cancer Taskforce, aimed at enhancing treatment, detection, and research about children’s cancer.
Breast cancer diagnostics occupy a noteworthy share of the global market
By application, the global cancer diagnostics market is fragmented into Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Ovarian Cancer, and Others. Breast cancer diagnostics claim one of the vast shares of the global market. This is due to the high prevalence and mortality rates associated with the disease. According to the World Health Organization (WHO), there have been 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. Routine screenings like mammograms are widely recommended for early detection, propelling demand for diagnostic equipment, including imaging modalities and biopsy strategies. Further, advancements in customized medicinal drugs and genetic testing augment the breast cancer diagnostics market, allowing tailored remedy processes. With a growing emphasis on early intervention and improved survival prices, breast cancer diagnostics stay a cornerstone in oncology practice.
Imaging tests are crucial in the global cancer diagnostics market
The global cancer diagnostics market is segmented by test type into Tumor Biomarkers Tests, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, and In Situ Hybridization. Imaging test types represent one of the most significant global cancer diagnostics market segments. This is due to their pivotal function in detecting, staging, and tracking cancers. Modalities like MRI, CT, PET, and ultrasound offer designated anatomical and functional data, aiding in precise analysis and remedy planning. With improvements in imaging technology like contrast-enhanced and molecular imaging, these assessments offer an increasing number of accurate and complete evaluations of tumors. As healthcare structures prioritize early detection and customized remedies, imaging test types remain fundamental to cancer diagnostics.
Diagnostic centers might continue to usher the global cancer diagnostics market
By end-user, the global cancer diagnostics market is classified into Diagnostic Centers, Hospitals and Clinics, Research Institutes, and Other segments. Diagnostic centers have emerged as one of the dominant segments in the global cancer diagnostics market. This is because of their specialized know-how and comprehensive offerings. These facilities provide diagnostic assessments, which include imaging, biopsies, and laboratory analyses, ensuring correct and well-timed cancer detection. With their cutting-edge device and experienced personnel, diagnostic facilities offer a centralized hub for patients and healthcare specialists seeking efficient and thorough cancer diagnostics.
United States Cancer Diagnostics Market
The United States can potentially preserve its lead in the global market during the projection period. This is due to the developing cancer burden and the growing awareness of clinical device organizations on developing novel diagnostic instruments that can hit upon cancer. Further, the initiatives the authorities took in this area are anticipated to boost the market increase. For example, in 2022, President Biden announced a renewed effort for the Cancer Moonshot to lessen cancer deaths by 50% in 25 years while enhancing the lives of people with cancer and survivors. So, the government helps cancer diagnosis drives, which might be believed to contribute to the increase of the global cancer diagnostics market.
Europe Cancer Diagnostics Market
The European market for cancer diagnostics is growing steadily because of the increase in the number of patients and innovations in diagnosis tools. Currently, governments as well as heath care system in developed countries such as Germany, France, and the United Kingdom are escalating on early detection and screening. Other aspects that create growth include the continually growing need for personalized medicine and advances in imaging technology.
Germany Cancer Diagnostics Market
Currently, Germany has a growing market for cancer diagnostics owing to an increased rate of cancer diagnosis and growing demand for diagnosis in their early stages. Investment in knowledge through funding of medical research and development of modern form of healthcare in Germany has made it possible for frequent and efficient use of new diagnostic tools like liquid biopsies, NGS and advanced image studies. The growing awareness campaigns by governments and nationally sanctioned cancer detection programmes especially breast, colon and lung cancer also boost market growth. Furthermore, increasing importance of both personalized medicine and individualized diagnostics brings continuous further development of cancer diagnostics in Germany. In 2022, Germany has been diagnosed with breast cancer 75,000, bowel cancer 62,000 and prostate cancer 65,000, new cases.
Saudi Arabia Cancer Diagnostics Market
Saudi Arabia based cancer diagnostics market is expanding due to rising incidence of cancer and increased healthcare expenditure. The Kenyan government’s vision 2030 documents focus on enhancement of health care services to include early detection of cancer and better diagnostic techniques. Recently, Saudi Arabia has been increasing investment in healthcare facilities, new or improved diagnostic technologies, including enhanced imaging studies and molecular diagnostics, to name a few. Community awareness and education and national cancer testing initiatives, especially for breast and colon cancer add to the market. Other drivers regarding growth of the cancer diagnostics market include the increasing use of personalized medicine and increased emphasis on better patient outcomes. Cancer incidence for new cases is likely to rise from a figure of 27,885 in 2020 to 60,429 in 2040.
Key Players
In the global cancer diagnostics market, prominent players include Illumina, Abbott Laboratories, Thermo Fisher Scientific, Inc., QIAGEN N.V., Roche Holding AG, Pfizer, Inc., Koninklijke Philips N.V., and bioMérieux.
• In April 2023 - Quest Diagnostics acquired Haystack Oncology in an all-cash deal to expand MRD testing services focusing on colorectal, breast, and lung cancers. The company targets to develop patient outcomes by detecting MRD early after treatment.
• In June 2023 - Blue Earth Diagnostics received FDA approval for POSLUMA, a high-affinity rh-PSMA-targeted PET imaging agent, for prostate cancer detection and localization. The innovative radio hybrid technology provides accurate imaging and potential therapeutic applications.
Application – Global Cancer Diagnostics Market breakup in 12 viewpoints:
1. Breast Cancer
2. Colorectal Cancer
3. Cervical Cancer
4. Lung Cancer
5. Prostate Cancer
6. Skin Cancer
7. Blood Cancer
8. Kidney Cancer
9. Liver Cancer
10. Pancreatic Cancer
11. Ovarian Cancer
12. Others
Test Type – Global Cancer Diagnostics Market breakup in 6 viewpoints:
1. Tumor Biomarkers Tests
2. Imaging
3. Biopsy
4. Liquid Biopsy
5. Immunohistochemistry
6. In Situ Hybridization
End-User – Global Cancer Diagnostics Market breakup in 4 viewpoints:
1. Diagnostic Centers
2. Hospitals and Clinics
3. Research Institutes
4. Others
Country – Global Cancer Diagnostics Market of 25 Countries:
1. North America
1.1 United States
1.2 Canada
2. Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey
3. Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
4. Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
5. Middle East & Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis
Company Analysis:
1. llumina
2. Abbott Laboratories
3. Thermo Fisher Scientific, Inc.
4. QIAGEN N.V.
5. Roche Holding AG.
6. Pfizer, Inc.
7. Koninklijke Philips N.V.
8. bioMérieux
Report Details:
| Report Features | Details |
| Base Year | 2023 |
| Historical Period | 2019 - 2023 |
| Forecast Period | 2024 - 2030 |
| Market | US$ Billion |
| Segment Covered | Application, Test Type, End User, and Countries |
| Countries Covered | United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, and New Zealand, Brazil, Mexico, Argentina, Saudi Arabia, United Arab Emirates, and South Africa |
| Companies Covered | Illumina, Abbott Laboratories, Thermo Fisher Scientific, Inc., QIAGEN N.V., Roche Holding AG, Pfizer, Inc., Koninklijke Philips N.V., and bioMérieux. |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Cancer Diagnostics Market
6. Market Share – Global Cancer Diagnostics Analysis
6.1 By Application
6.2 By Test Type
6.3 By EndUsers
6.4 By Country
7. Application – Global Cancer Diagnostics Market
7.1 Breast Cancer
7.2 Colorectal Cancer
7.3 Cervical Cancer
7.4 Lung Cancer
7.5 Prostate Cancer
7.6 Skin Cancer
7.7 Blood Cancer
7.8 Kidney Cancer
7.9 Liver Cancer
7.10 Pancreatic Cancer
7.11 Ovarian Cancer
7.12 Others
8. Test Type – Global Cancer Diagnostics Market
8.1 Tumor Biomarkers Tests
8.2 Imaging
8.3 Biopsy
8.4 Liquid Biopsy
8.5 Immunohistochemistry
8.6 In Situ Hybridization
9. End-User – Global Cancer Diagnostics Market
9.1 Diagnostic Centers
9.2 Hospitals and Clinics
9.3 Research Institutes
9.4 Others
10. Country – Global Cancer Diagnostics Market
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 France
10.2.2 Germany
10.2.3 Italy
10.2.4 Spain
10.2.5 United Kingdom
10.2.6 Belgium
10.2.7 Netherlands
10.2.8 Turkey
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Thailand
10.3.6 Malaysia
10.3.7 Indonesia
10.3.8 Australia
10.3.9 New Zealand
10.4 Latin America
10.4.1 Brazil
10.4.2 Mexico
10.4.3 Argentina
10.5 Middle East & Africa
10.5.1 Saudi Arabia
10.5.2 UAE
10.5.3 South Africa
11. Porter’s Five Analysis – Global Cancer Diagnostics Market
11.1 Bargaining Power of Buyers
11.2 Bargaining Power of Suppliers
11.3 Degree of Rivalry
11.4 Threat of New Entrants
11.5 Threat of Substitutes
12. SWOT Analysis – Global Cancer Diagnostics Market
12.1 Strength
12.2 Weakness
12.3 Opportunity
12.4 Threat
13. Company Analysis – Global Cancer Diagnostics Market
13.1 llumina
13.1.1 Overviews
13.1.2 Recent Developments
13.1.3 Revenues
13.2 Abbott Laboratories
13.2.1 Overviews
13.2.2 Recent Developments
13.2.3 Revenues
13.3 Thermo Fisher Scientific, Inc
13.3.1 Overviews
13.3.2 Recent Developments
13.3.3 Revenues
13.4 QIAGEN N.V.
13.4.1 Overviews
13.4.2 Recent Developments
13.4.3 Revenues
13.5 Roche Holding AG.
13.5.1 Overviews
13.5.2 Recent Developments
13.5.3 Revenues
13.6 Pfizer, Inc.
13.6.1 Overview
13.6.2 Recent Development
13.6.3 Financial Insights
13.7 Koninklijke Philips N.V.
13.7.1 Overview
13.7.2 Recent Development
13.7.3 Financial Insights
13.8 bioMérieux
13.8.1 Overview
13.8.2 Recent Development
13.8.3 Financial Insights
List of Figures:
Figure-01: Global – Cancer Diagnostics Market (Billion US$), 2019 – 2023
Figure-02: Global – Forecast for Cancer Diagnostics Market (Billion US$), 2024 – 2030
Figure-03: Application – Breast Cancer Market (Million US$), 2019 – 2023
Figure-04: Application – Forecast for Breast Cancer Market (Million US$), 2024 – 2030
Figure-05: Application – Colorectal Cancer Market (Million US$), 2019 – 2023
Figure-06: Application – Forecast for Colorectal Cancer Market (Million US$), 2024 – 2030
Figure-07: Application – Cervical Cancer Market (Million US$), 2019 – 2023
Figure-08: Application – Forecast for Cervical Cancer Market (Million US$), 2024 – 2030
Figure-09: Application – Lung Cancer Market (Million US$), 2019 – 2023
Figure-10: Application – Forecast for Lung Cancer Market (Million US$), 2024 – 2030
Figure-11: Application – Prostate Cancer Market (Million US$), 2019 – 2023
Figure-12: Application – Forecast for Prostate Cancer Market (Million US$), 2024 – 2030
Figure-13: Application – Skin Cancer Market (Million US$), 2019 – 2023
Figure-14: Application – Forecast for Skin Cancer Market (Million US$), 2024 – 2030
Figure-15: Application – Blood Cancer Market (Million US$), 2019 – 2023
Figure-16: Application – Forecast for Blood Cancer Market (Million US$), 2024 – 2030
Figure-17: Application – Kidney Cancer Market (Million US$), 2019 – 2023
Figure-18: Application – Forecast for Kidney Cancer Market (Million US$), 2024 – 2030
Figure-19: Application – Liver Cancer Market (Million US$), 2019 – 2023
Figure-20: Application – Forecast for Liver Cancer Market (Million US$), 2024 – 2030
Figure-21: Application – Pancreatic Cancer Market (Million US$), 2019 – 2023
Figure-22: Application – Forecast for Pancreatic Cancer Market (Million US$), 2024 – 2030
Figure-23: Application – Ovarian Cancer Market (Million US$), 2019 – 2023
Figure-24: Application – Forecast for Ovarian Cancer Market (Million US$), 2024 – 2030
Figure-25: Application – Others Market (Million US$), 2019 – 2023
Figure-26: Application – Forecast for Others Market (Million US$), 2024 – 2030
Figure-27: Test Type – Tumor Biomarkers Tests Market (Million US$), 2019 – 2023
Figure-28: Test Type – Forecast for Tumor Biomarkers Tests Market (Million US$), 2024 – 2030
Figure-29: Test Type – Imaging Market (Million US$), 2019 – 2023
Figure-30: Test Type – Forecast for Imaging Market (Million US$), 2024 – 2030
Figure-31: Test Type – Biopsy Market (Million US$), 2019 – 2023
Figure-32: Test Type – Forecast for Biopsy Market (Million US$), 2024 – 2030
Figure-33: Test Type – Liquid Biopsy Market (Million US$), 2019 – 2023
Figure-34: Test Type – Forecast for Liquid Biopsy Market (Million US$), 2024 – 2030
Figure-35: Test Type – Immunohistochemistry Market (Million US$), 2019 – 2023
Figure-36: Test Type – Forecast for Immunohistochemistry Market (Million US$), 2024 – 2030
Figure-37: Test Type – In Situ Hybridization Market (Million US$), 2019 – 2023
Figure-38: Test Type – Forecast for In Situ Hybridization Market (Million US$), 2024 – 2030
Figure-39: End-User – Diagnostic Centers Market (Million US$), 2019 – 2023
Figure-40: End-User – Forecast for Diagnostic Centers Market (Million US$), 2024 – 2030
Figure-41: End-User – Hospitals and Clinics Market (Million US$), 2019 – 2023
Figure-42: End-User – Forecast for Hospitals and Clinics Market (Million US$), 2024 – 2030
Figure-43: End-User – Research Institutes Market (Million US$), 2019 – 2023
Figure-44: End-User – Forecast for Research Institutes Market (Million US$), 2024 – 2030
Figure-45: End-User – Others Market (Million US$), 2019 – 2023
Figure-46: End-User – Forecast for Others Market (Million US$), 2024 – 2030
Figure-47: United States – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-48: United States – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-49: Canada – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-50: Canada – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-51: France – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-52: France – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-53: Germany – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-54: Germany – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-55: Italy – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-56: Italy – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-57: Spain – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-58: Spain – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-59: United Kingdom – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-60: United Kingdom – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-61: Belgium – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-62: Belgium – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-63: Netherlands – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-64: Netherlands – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-65: Turkey – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-66: Turkey – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-67: China – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-68: China – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-69: Japan – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-70: Japan – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-71: India – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-72: India – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-73: South Korea – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-74: South Korea – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-75: Thailand – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-76: Thailand – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-77: Malaysia – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-78: Malaysia – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-79: Indonesia – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-80: Indonesia – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-81: Australia – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-82: Australia – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-83: New Zealand – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-84: New Zealand – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-85: Brazil – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-86: Brazil – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-87: Mexico – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-88: Mexico – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-89: Argentina – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-90: Argentina – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-91: Saudi Arabia – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-92: Saudi Arabia – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-93: UAE – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-94: UAE – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-95: South Africa – Cancer Diagnostics Market (Million US$), 2019 – 2023
Figure-96: South Africa – Forecast for Cancer Diagnostics Market (Million US$), 2024 – 2030
Figure-97: llumina – Global Revenue (Million US$), 2019 – 2023
Figure-98: llumina – Forecast for Global Revenue (Million US$), 2024 – 2030
Figure-99: Abbott Laboratories – Global Revenue (Million US$), 2019 – 2023
Figure-100: Abbott Laboratories – Forecast for Global Revenue (Million US$), 2024 – 2030
Figure-101: Thermo Fisher Scientific, Inc – Global Revenue (Million US$), 2019 – 2023
Figure-102: Thermo Fisher Scientific, Inc – Forecast for Global Revenue (Million US$), 2024 – 2030
Figure-103: QIAGEN N.V. – Global Revenue (Million US$), 2019 – 2023
Figure-104: QIAGEN N.V. – Forecast for Global Revenue (Million US$), 2024 – 2030
Figure-105: Roche Holding AG. – Global Revenue (Million US$), 2019 – 2023
Figure-106: Roche Holding AG. – Forecast for Global Revenue (Million US$), 2024 – 2030
Figure-107: Pfizer, Inc. – Global Revenue (Million US$), 2019 – 2023
Figure-108: Pfizer, Inc. – Forecast for Global Revenue (Million US$), 2024 – 2030
Figure-109: Koninklijke Philips N.V. – Global Revenue (Million US$), 2019 – 2023
Figure-110: Koninklijke Philips N.V. – Forecast for Global Revenue (Million US$), 2024 – 2030
Figure-111: bioMérieux – Global Revenue (Million US$), 2019 – 2023
Figure-112: bioMérieux – Forecast for Global Revenue (Million US$), 2024 – 2030
List of Tables:
Table-01: Global – Cancer Diagnostics Market Share by Application (Percent), 2019 – 2023
Table-02: Global – Forecast for Global Cancer Diagnostics Market Share by Application (Percent), 2024 – 2030
Table-03: Global – Cancer Diagnostics Market Share by Test Type (Percent), 2019 – 2023
Table-04: Global – Forecast for Global Cancer Diagnostics Market Share by Test Type (Percent), 2024 – 2030
Table-05: Global – Cancer Diagnostics Market Share by End User (Percent), 2019 – 2023
Table-06: Global – Forecast for Global Cancer Diagnostics Market Share by End User (Percent), 2024 – 2030
Table-07: Global – Cancer Diagnostics Market Share by Countries (Percent), 2019 – 2023
Table-08: Global – Forecast for Global Cancer Diagnostics Market Share by Countries (Percent), 2024 – 2030
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com